MACRILEN (US and Canada Rights) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 2

MACRILEN (US and Canada Rights) General Information

Description

A portfolio of distribution and development rights of an oral growth hormone drug. The drug is used to diagnose and treat Adult Growth Hormone Deficiency in patients.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 315 Sigma Drive
  • Suite 302D
  • Charleston, SC 29486
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Novo Nordisk
Corporate Office
  • 315 Sigma Drive
  • Suite 302D
  • Charleston, SC 29486
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MACRILEN (US and Canada Rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MACRILEN (US and Canada Rights)‘s full profile, request access.

Request a free trial

MACRILEN (US and Canada Rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore MACRILEN (US and Canada Rights)‘s full profile, request access.

Request a free trial

MACRILEN (US and Canada Rights) FAQs

  • Where is MACRILEN (US and Canada Rights) headquartered?

    MACRILEN (US and Canada Rights) is headquartered in Charleston, SC.

  • What industry is MACRILEN (US and Canada Rights) in?

    MACRILEN (US and Canada Rights)’s primary industry is Buildings and Property.

  • Is MACRILEN (US and Canada Rights) a private or public company?

    MACRILEN (US and Canada Rights) is a Private company.

  • What is the current valuation of MACRILEN (US and Canada Rights)?

    The current valuation of MACRILEN (US and Canada Rights) is .

  • What is MACRILEN (US and Canada Rights)’s current revenue?

    The current revenue for MACRILEN (US and Canada Rights) is .

  • Who are MACRILEN (US and Canada Rights)’s investors?

    COSCIENS Biopharma and Strongbridge Biopharma have invested in MACRILEN (US and Canada Rights).

  • When was MACRILEN (US and Canada Rights) acquired?

    MACRILEN (US and Canada Rights) was acquired on 19-Dec-2018.

  • Who acquired MACRILEN (US and Canada Rights)?

    MACRILEN (US and Canada Rights) was acquired by Novo Nordisk.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process